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All colorectal cancer cell lines except RKO displayed active 𝛽-catenin/TCF regulated transcription. This feature of RKO was noted
in familial colon cancers; hence our aim was to dissect its carcinogenic mechanism. MFISH and CGH revealed distinct instability
of chromosome structure in RKO. Gene expression microarray of RKO versus 7 colon cancer lines (with active Wnt signaling) and
3 normal specimens revealed 611 differentially expressed genes. The majority of the tested gene loci were susceptible to LOH in
primary tumors with various 𝛽-catenin localizations as a surrogate marker for 𝛽-catenin activation. The immunohistochemistry
of selected genes (IFI16, RGS4, MCTP1, DGKI, OBCAM/OPCML, and GLIPR1) confirmed that they were differentially expressed
in clinical specimens. Since epigenetic mechanisms can contribute to expression changes, selected target genes were evaluated for
promoter methylation in patient specimens from sporadic and hereditary colorectal cancers. CMTM3, DGKI, and OPCML were
frequently hypermethylated in both groups, whereasKLK10, EPCAM, andDLC1 displayed subgroup specificity.The overall fraction
of hypermethylated genes was higher in tumors withmembranous𝛽-catenin.We identified novel genes in colorectal carcinogenesis
that might be useful in personalized tumor profiling. Tumors with inactive Wnt signaling are a heterogeneous group displaying
interaction of chromosomal instability, Wnt signaling, and epigenetics.
1. Introduction
Early research into the role of APC mutations in colorectal
carcinogenesis showed that the majority of colorectal cancer
cell lines have acquired activated 𝛽-catenin/TCF regulated
transcription and hence active canonical Wnt signaling path-
way, as a result of inactivation of APC or activatingmutations
of 𝛽-catenin gene CTNNB1 [1].This finding was confirmed in
further studies on cell lines and primary tumors [2, 3]. The
Cancer Genome Atlas Research Network showed that 93% of
colorectal cancers hadmutations in this pathway; most often,
these changes appeared in the APC tumor suppressor gene
[4]. Exceptionally, the cell line RKOdid not havemutations in
APC or CTNNB1 and did not show any evidence of activated
𝛽-catenin/TCF regulated transcription [2, 5]. This finding
was of interest to cancer researchers and was confirmed in
separate study through robust functional analyses [5]. In
primary colorectal tumors, immunohistochemical detection
of 𝛽-catenin subcellular localization was established as a
surrogate marker for its activity, where nuclear 𝛽-catenin
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localization indicated activated 𝛽-catenin/TCF regulated
transcription and membranous localization of 𝛽-catenin
indicated inactive 𝛽-catenin/TCF regulated transcription.
Using this approach, the majority of primary colon tumors
showed nuclear 𝛽-catenin with the exception of few subsets
including familial colon cancer [6]. Hence, investigation of
carcinogenic mechanisms in such category might uncover
novel pathways in colorectal carcinogenesis.
Extensive studies showed that genetic instability and
epigenetic changes play a significant role in colorectal car-
cinogenesis. Different patterns of genetic instability were
described in colorectal cancers including chromosomal insta-
bility which may have diverse underlying causes and
microsatellite instability (MSI) due to deficiency in the mis-
match repair (MMR) system [7]. Chromosomal instability
could affect chromosomal number and/or structure [8] and
the latter could manifest as gross structural rearrangements
and/or subtle changes resulting in loss of heterozygosity
(LOH). Further studies into the mechanisms of LOH devel-
opment showed that environmental carcinogens have the
ability to induce genome-wide LOH without persistent chro-
mosomal instability [9]. Epigenetic alterations could also
reflect the effect of the environmental toxins and/or ethnicity
[10]. Interestingly, chromosomal instability, MSI, and epige-
netics were shown to be independent prognostic factor in
stage II/III colorectal cancer [11, 12].Therefore, to understand
the carcinogenesis of cells lacking 𝛽-catenin/TCF regulated
transcription, it is important to address the interaction of
these mechanisms in such cells.
We compared the RKO cell lines to seven classical col-
orectal cancer cell lines (with activeWnt signaling) and three
normal colon mucosa specimens. The seven cell lines were
chosen to be MSI similar to RKO, to eliminate the influence
of this mechanism.
2. Materials and Methods
2.1. Patients and Samples. The colon cancer cell lines were
RKO, HCA7, KM12, LoVo, HCT15, HCT116, SW48, and
LIM1215. RKOwas the only cell line with nomutation inAPC
or CTNNB1. To maintain this as the differentiating factor,
cell lines for microarray analysis were selected to be MSI
similar to RKOand,moreover, themajority of these cells were
CpG island methylator phenotype- (CIMP-) positive similar
to RKO.Many of these features were confirmed in our lab (see
Section 3).We included three, high purity normal colon RNA
samples (from Ambion/Life Technologies) in the microarray
analysis. The primary colorectal samples for methylation
analysis consisted of 110 colorectal cancers from Finland,
including 27 from Lynch syndrome families and 83 spo-
radic tumors [13, 14]. For immunohistochemistry, there were
additional sections from 12 sporadic adenomas, 38 can-
cers from 11 Finnish Lynch syndrome families, and 19
specimens representing Familial Colorectal Cancer Type X
(FCCX), hereditary nonpolyposis colorectal carcinomawith-
out DNAmismatch repair defects. Tumors were examined by
microsatellite instability testing andMMRprotein expression
studies by immunohistochemical staining [13]. For the LOH,
a pilot study was performed on 22 MSS sporadic cancers
(12 with nuclear and 10 with membranous 𝛽-catenin). Fresh
frozen and/or paraffin derived specimens of tumor and
matching normal tissues were collected from pathology
departments of different hospitals and used for immunohis-
tochemical analysis and DNA extraction according to stan-
dard protocols. The study was approved by the institutional
review board of the Helsinki University Central Hospital
(Dnro 466/E6/01) and the National Authority for Medicole-
gal Affairs (Dnro 1272/04/044/07).
2.2. APC, CTNNB1, and BRAF Mutations. APC mutation
analysis was as described [15]. CTNNB1 exon 3 was directly
sequenced as described [6]. BRAF mutation analysis focused
on codon 600 and was conducted as described in Niskakoski
et al. [16].
2.3. M-FISH and CGH. Multiplex fluorescence in situ
hybridization (M-FISH) was performed using the Xcyting
colors (MetaSystems GmbH, Altlussheim, Germany) accord-
ing to the manufacturer’s protocol. Data were analysed
using ISIS 4.4.21 software (MetaSystems GmbH). Compar-
ative genomic hybridization (CGH) was performed and
results were analyzed according standard protocols. Briefly,
tumor DNA and reference DNA (genomic DNA from
peripheral blood leukocytes from normal donors) were
labelled by nick translation with fluorescein-iso-thiocyanate
(FITC)-conjugated dCTP and dUTP (DuPont, Boston, MA,
USA), and Texas Red-conjugated dCTP and dUTP (Dupont),
respectively, to obtain fragments ranging from 600 to
2000 bp. The results were analyzed using the ISIS digital
image analysis system (MetaSystems GmbH, Altlussheim,
Germany), based on an integrated high-sensitivity mono-
chrome charge-coupled device (CCD) camera and automated
CGH analysis software.
2.4. Gene Expression Microarray. Gene expression was ana-
lyzed using Affymetrix Human Genome U133 Plus 2.0
GeneChip® microarrays (Affymetrix, Santa Clara, CA), con-
taining over 54 000 probe sets covering 47 000 transcripts.
The samples for microarray were biological duplicates of all
the 8 cell lines plus the three normal mucosal specimens.
2.4.1. Preparation of RNA. Total RNA was extracted and
purified using Qiagen RNeasy kit (Qiagen Inc., Valencia,
CA, USA). RNA integrity and yield were assessed by Agilent
Bioanalyzer 2100 (Agilent Technologies, CA, USA). Only
samples with an RNA integrity number (RIN) higher than 7.0
were included in the analysis.
2.4.2. Hybridization and Image Analysis. Samples were
amplified, labelled and hybridized according to manufac-
turer’s protocol and as described in Nymark et al. [19].
The arrays were washed and stained with streptavidin-
phycoerythrin in an Affymetrix GeneChip Fluidics station
450, and scanned with Affymetrix GeneChip Scanner 3000.
The image was analyzed using the GeneChip operating soft-
ware (GCOS; Affymetrix, Santa Clara, CA) and comparison
analysis was done according to the instructions provided by
the manufacturer. After image acquisition, raw fluorescent
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signal (cel. file) from Affymetrix GeneChip Operating Soft-
ware (GCOS) was used for analysis.
Microarray data were analyzed using GeneSpring GX12.0
software and processed using robust multiarray analysis
(RMA) algorithm for background correction, normaliza-
tion and log2-transformation. Unpaired 𝑡-test analysis with
Benjamini-Hochberg multiple testing correction was utilized
to obtain genes whose fold change between Wnt inactive
and Wnt active colorectal cancer cell lines was ≥2.0 (with 𝑃
value cut-off of <0.05). Unsupervised hierarchical clustering
analysis was performed in GeneSpring software on nor-
malised data for differentially expressed genes for all samples.
The euclidean distance metric was used, this calculates the
standard sum of squared distance between two entities, with
centroid linkage (distance between two clusters is calculated
as the average distance between their respective centroids
weighted by the size of the clusters).The rawmicroarray data
are deposited at GEO with the accession number GSE58058.
Pathway analysis was performed at the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7, NIAID, NIH at http://david.abcc.ncifcrf.gov/
home.jsp using KEGG and Biocarta annotation.
2.5.MSI and LOHAnalysis. MSI statuswas determined using
the Bethesda panel (BAT25, BAT26, D5S346, D2S123, and
D17S250; [20]). The 31 dinucleotide repeat markers used for
LOH analyses (Supplementary Table S1, in Supplementary
Material available online at http://dx.doi.org/10.1155/2016/
6089658) had high allele number and heterozygosity fre-
quency. Primer sequences and PCR amplification conditions
were retrieved through NCBI website (http://www.ncbi.nlm
.nih.gov/). The experimental procedure and data analysis
were as described [6]. Tumors with two or more unstable
markers, or BAT25 or BAT26 instability alone were consid-
ered as having high-degreemicrosatellite instability (MSI-H).
LOH study was performed on 22 cancers from the sporadic
MSS series (12 with nuclear and 10 with membranous 𝛽-
catenin).
2.6. Immunohistochemistry. Theprimary antibodies are listed
in Supplementary Table S2. Immunohistochemistry was per-
formed as described before [21] on a pilot series of 22 carci-
nomas (12 with nuclear 𝛽-catenin and 10 with membranous
𝛽-catenin) and then was extended to include all available
sections.
2.7. Methylation Analysis. Methylation analysis was con-
ducted byMethylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA). In brief, promoter-
associated CpG islands were examined for methylation by
bisulphite sequencing with primers indicated in Supplemen-
tary Table S3-A and representative HhaI sites used for
MS-MLPA probe design according to the protocol of MRC-
Holland (Supplementary Table S3-B). Upon digestion of the
sample DNA/probe hybrids with the methylation sensitive
restriction enzyme HhaI, only samples with the HhaI site
methylated will generate an amplification product. Synthetic
MS-MLPA probes for the chosen genes were added to the
P300 commercial test (SALSA MLPA P300-A1 Reference-2
kit, MRC-Holland, Amsterdam, the Netherlands) for control
fragments. The DLC1 gene had two separate MS-MLPA
probes, with the probe for DLC1 isoform 4 (DLC1-i4)
designed based on a previous publication [22]. Methylation
dosage ratios (𝐷
𝑚
values) were calculated as described [23].
CustomMS-MLPA assays were validated against bisulfite
sequencing by using normal tissue and cancer cell lines. The
technical threshold for methylation detection by MS-MLPA
was 0.15 for all loci since 𝐷
𝑚
<0.15 by MS-MLPA correlated
with the lack of methylation (T/T) by bisulphite sequencing,
whereas 𝐷
𝑚
>0.15 correlated with methylation (C/T or C/C)
by bisulphite sequencing. To evaluate increased methylation
in tumor DNA versus normal DNA (i.e., hypermethylation),
a normal tissue-based hypermethylation threshold was deter-
mined individually for each locus. The hypermethylation
threshold was defined as the average 𝐷
𝑚
+1 standard devi-
ation and derived from the combined set of normal mucosa
specimens (𝑛 = 110) from all patient groups (Supplementary
Table S4).
2.8. Statistical Analysis. Statistical analyses were performed
using SPSS Statistics Software (IBM SPSS, Inc., Chicago, IL,
USA). The percentages of tumors with hypermethylation
were compared by Fisher Exact Probability Test from Vas-
sarStats Web site (http://www.vassarstats.net/tab2x2.html).
Independent samples 𝑡-test was used for comparisons of two
normally distributed tumor groups. One-way ANOVA was
used for statistical analyses of normally distributed data.
Whenmethylation patterns between normal and tumor sam-
ples were examined parametric 𝑡-test for paired samples or
nonparametric paired-samples Wilcoxon signed rank test
was used. 𝑃 values <0.05 (two-tailed) were considered signif-
icant.
3. Results
3.1. MSI, APC, and CTNNB1 Status Showed That RKO Is
Unique in Having Nonmutant APC/CTNNB1. RKO was the
only cell line with no mutation in APC or CTNNB1. To
maintain this as the a differentiating factor, cell lines for
microarray analysis were selected to be MSI similar to RKO
and the majority of these cells were CpG island methylator
phenotype- (CIMP-) positive similar to RKO as well. We
considered it important that these cell lines used for compar-
ison shared these characteristics. The MSI status and the 𝛽-
catenin gene (CTNNB1) mutation status were confirmed in
our lab during previous studies [13, 24]. The APC gene was
fully sequenced in the 3 cell lines HCA7, KM12, and RKO in
our laboratory [24]. We found no mutations in RKO whereas
frame shift mutations due to insertions of one nucleotide
in exon 15 were present in the HCA7 and KM12 cell lines.
The KM12 mutation was “c.5454 5455insA” and the HCA7
mutation was “c.4667 4668insA” as compared to GenBank
accession number RefSeqM74088.1 (Supplementary Table
S5).
Since RKO was the among the only in vitro colorectal
cancer model holding BRAF mutation; we also extended the
BRAF mutation analysis to the primary tumors. We found
that BRAF V600E mutation was present as follows: sporadic
4 Gastroenterology Research and Practice
Table 1: Cytogenetic characteristics of RKO cell line compared to MSI and MSS cell lines.
Cell line Aneuploid Indexa
Variability of
centromere
numberb
Rearranged
Chromosomes by
M-FISH/SKY
Copy number
changes by CGH
RKO 2 1 14 9
MSI cell lines 1–8 (3.1) 1–3 (2) 0–5 (2.7) 0–4 (2.4)
MSS cell lines 8–19 (14.2) 6–30 (15.4) 9–24 (15.8) 11–30 (19.4)
aThe aneuploid index was calculated as the sum of all the consistent chromosomal gains or losses present in the karyotype. Thus, for each monosomy or each
trisomy present, a score of 1 was contributed to the aneuploid index. The aneuploid index is different from the modal chromosome number because of cell to
cell variability in the presence or absence of a specific chromosome. bThe variability of centromere numbers was calculated by counting in each of the examined
metaphases the number of copies of each centromere, whether in normal or rearranged copies of a chromosome; noting the percentage of metaphases that
have deviations from the modal centromere number; and averaging over all centromeres. The data of the MSS and MSI cell lines, shown as range followed by
average, were pooled from the published literature [8, 17, 18] omitting the newest duplicate data in chronological order and excluding the nonclassical cell lines
C70, HCA7, and LS411.
MSI-colorectal cancers 17/33 (51%) (result was not available
for 7), sporadicMSS- colorectal cancers 0/40 (0%) (result was
not available for 3), and Lynch syndrome-colorectal cancers
0/15 (0%) (result was not available for 12).
3.2. M-FISH and CGH Profile of RKO Are Unique. The RKO
karyotype by M-FISH (Figure 1) showed marked metaphase-
to-metaphase heterogeneity. The karyotype of the most
common clone (14/20 metaphases) was 47 (44∼49), XX,
del(2)(p21), der(3)t(3;5), del(5q), dup(7)(q21q36), +der(8)t(8;
8)(p12;q21), del(9), +der(12)t(2;12), +der(20)t(9;20)(q22;p13),
and der(22)t(16;22). In addition, there were some structural
rearrangements present in two or more of the metaphases
such as del(X), del(6p), der(12)t(5;12), der(10)t(2;10)(p21;q11),
and der(20)t(2;20). To identify the nature of chromosomal
instability and to allow comparison with the published kary-
otype of other colon cancer cell lines, variety of indices were
calculated and compared to classical MSI and MSS cell lines
from the published literature (Table 1). The total “aneuploid
index” [17] equals the sum of all the nondisjunctional events
required to generate the aberrant chromosome complement
in a given cancer cell line. As shown in Table 1, the RKO
cell line has a stable aneuploid index typical of the MSI cell
lines [17]. The variability of centromere numbers [8] showed
that RKO also had no numerical chromosomal instability
similar to the MSI cell lines (Table 1). The number of
rearranged chromosomes was used as ameasure of instability
of chromosome structure. RKO cell line had 14 rearranged
chromosomes that were noted in two or more metaphases.
This number was rather typical of the MSS cell lines. The
CGH showed 9 copy number changes in RKOwhich were rev
ish enh(7q21qter, 8q11qter, 9q22qter, 12pterq14, 16q22qter, 20,
22), amp(8q22qter, 9q34qter).This number was also closer to
the MSS cells. Hence, both the M-FISH and CGH indepen-
dently revealed instability of chromosome structure in RKO.
Karyotypes of other cell lines used here were available
in previous publication by our group [8] or others [25, 26]
except for LIM1215 which was karyotyped here for the first
time by a molecular cytogenetic technique and it showed a
stable karyotype, 46 (45–47), XY, del(3p), and der(13)t(1;13),
consistent with being MSI line.
Figure 1: A representative metaphase from RKO cell line. Note that
rearranged chromosomes described in Section 3 and not seen here
were observed in two or more other metaphases.
3.3. Expression Microarray Revealed Many Interesting Can-
didate Genes. In order to discover global gene expression
patterns characterizing the rare colon cancer subgroup lack-
ing constitutive 𝛽-catenin/TCF regulated transcription, the
RKO cell line cDNA expression profile was compared to 10
specimens: 7 MSI colon cancer lines and three normal colon
mucosa samples as described above. Taking a twofold change
as threshold limit, there were 815 differentially expressed
Affymetrix probes (272 downregulated and 543 upregulated)
in RKO compared to Wnt-active colon cancer cell lines. The
probes corresponded to 611 unique genes (399 downregulated
and 212 downregulated, Supplementary Table S6). Cluster
analysis showed that samples clustered into 3 distinct groups
with RKO duplicate samples in one group, the normal sam-
ples in one group, and all other cancer cell lines in one group
(Figure 2). Pathway analysis of the differentially expressed
genes revealed that at least 20 pathways were affected includ-
ing insulin signaling, ErbB signaling, T cell receptor signaling
pathway and apoptosis. Wnt signaling pathway itself was
represented by 3 differentially expressed genes (CCND3,
PPP3CA, and PPP3CC). For accurate identification of 𝛽-
catenin targets we compared our list to recent literature of
Wnt targets in colon cancer [27]. We identified 23Wnt target
genes from our list when compared to Herbst et al. list of
335 genes. These were reduced to 17 genes when compared
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Figure 2: Cluster analysis based on the cDNA expression profiling of all colorectal cancer cell lines and normal colon specimens.The analysis
was performed on GeneSpring GX software, version 11.0.2, Agilent Technologies.
to the most stringent list of 193 identified by Herbst et al. [27]
after they compared their data to the previous literature. Our
17 genes were ABCC3, BCL10, BCL2L11, C19orf33, C4orf34,
DUSP3, ELF3, GPRC5A, KLHL29, MYOF, NAV3, RBM47,
RNF43, S100A10, TEX10, TJP2, and TNS3.
3.4. LOH of the Selected Target Genes Was Common. A total
of 31 dinucleotide markers were analyzed for LOH in infor-
mative cases (i.e., heterozygous MSS cases) (Supplementary
Table S1 and Figure 3). These markers were selected to be
spread along the whole genome and to be close to differ-
entially expressed genes from the microarrays. Both tumor
categories, those with and without activeWnt signaling, were
susceptible to LOH. All tested loci with the exception of
2q24.3 showed some degree of LOH in primary tumors.
Overall, LOH frequency was slightly lower in tumors with
inactiveWnt signaling but this did not reach statistical signif-
icance. Some of the loci such as D7S2564, D7S662, D8S552,
D12S1728, D17S1353, D20S874, and D20S171 showed high
overall frequency of LOH in more than 50% of the informa-
tive cases. 2p25.1 and 2q11.2 provided the best example of loci
that were preferentially lost in one category (Figure 3). The
results illustrated that many of the differentially expressed
genes were also susceptible to LOH in primary tumors.
3.5. Immunohistochemistry Analysis of Target Genes. Genes
with cancer-relevant function and with antibodies available
were selected from the list of differentially expressed genes
to be further evaluated by immunohistochemistry. The
immunohistochemical staining results are shown in Table 2.
Six genes selected for this analysis (IFI16, RGS4, MCTP1,
DGKI, OBCAM/OPCML, and GLIPR1) showed variation of
protein expression among the 22 tumors of the pilot study. For
RGS4, DGKI, OBCAM/OPCML, and GLIPR1 proteins, stain-
ing was extended to include all tumors available. Expression
ofDGKI andGLIPR1 showed significant relationshipwith the
𝛽-catenin subcellular localization in a pattern similar to that
observed in the microarray analysis of the cell lines (Table 2).
Examples of the immunohistochemical staining are shown in
supplementary Figure SF1.
3.6. Promoter Methylation of Target Genes Was Associ-
ated with 𝛽-Catenin Status. As promoter methylation can
underlie expression changes, six genes from the cell line
experiments, all with verified or putative roles in growth
regulation andwith CpG islands in the promoter region, were
selected for methylation analyses by MS-MLPA. Four genes
exhibited high expression in RKO compared to the otherMSI
colon cancer cell lines (CMTM3, DGKI, OPCML, and DLC1)
whereas two genes had low gene expression in RKO (EPCAM
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Figure 3: High frequency of LOH at all tested loci in 22 sporadicMSS colorectal cancers (12 with nuclear and 10 withmembranous 𝛽-catenin)
indicates significant role of the differentially expressed genes in carcinogenesis.
and KLK10). DLC1 showed a fold change <2 in the microar-
ray analysis but it was included because of its potential
significance as a tumor suppressor in colon and liver cancers
[28, 29]. We found that the methylation status of these genes
in the cell lines was generally consistent with the expression
status from themicroarray experiment (Supplementary Table
S7).
Since the baseline levels of methylation may show locus
and patient group-specific variation, thresholds for hyperme-
thylation were determined as described in Section 2 and Sup-
plementary Table S4 and used to compare tumors from the
different patient groups (by Fisher’s exact test). Three genes
(CMTM3, DGKI, and OPCML) revealed high frequencies
of hypermethylation (78–98%) and no apparent subgroup-
specificity. KLK10 and EPCAM showed Lynch syndrome-
specific methylation patterns. For KLK10, 48% of Lynch
colorectal tumors showed hypermethylation compared to 8%
of sporadicMSI (𝑃 < 0.001) and 12% of sporadicMSS tumors
(𝑃 < 0.001). Hypermethylation of EPCAM was restricted to
Lynch syndrome colorectal cancers (30% versus 0% in the
sporadic groups; 𝑃 < 0.001). DLC1 hypermethylation was
characteristic of sporadic MSI colorectal cancer as compared
to Lynch (28% versus 0% detected by the DLC1 probe, 𝑃 <
0.01) or sporadic MSS colorectal cancer (28% versus 5%
detected by the DLC1 i4 probe, 𝑃 < 0.01).
To investigate the relationship between promoter hyper-
methylation and 𝛽-catenin subcellular localization, the num-
ber of gene promoters showing hypermethylation out of 7
(corresponding to the six genes examined, with two separate
promoter regions, DLC1 and DLC1 i4, for DLC1) was calcu-
lated for each tumor and comparedwith nuclear versusmem-
branous localization of 𝛽-catenin. In all three patient groups
(Lynch syndrome, sporadicMSI, and sporadicMSS colorectal
cancers, resp.), membranous 𝛽-catenin was associated with
a higher number of hypermethylated loci (3.4, 3.5, and 3.8),
compared with tumors showing nuclear 𝛽-catenin (3.1, 2.7,
and 2.9). As evident, the association of hypermethylation
with 𝛽-catenin status was stronger among sporadic (MSI
plus MSS combined) than Lynch-associated colorectal can-
cers, and reached statistical significance among the former
tumors (3.6 versus 2.8 in sporadic tumors with membranous
versus nuclear 𝛽-catenin, 𝑃 = 0.020 by ANOVA).
4. Discussion
Colorectal tumors are dominated by APC mutations which
almost always cause deletion of both central domains that
interact with 𝛽-catenin and C-terminal domains that interact
with the cytoskeleton and play a role in microtubule binding,
cell polarity, and chromosome segregation. Hence, deletion
of APC C-terminal domains is expected to contribute to the
chromosomal instability observed in many colorectal can-
cers. We have analyzed the chromosomal instability in RKO
by M-FISH and CGH which revealed almost stable chromo-
somal number as evidenced by low aneuploid index and low
variability of centromere number in RKO similar to the chro-
mosomally stable MSI lines. This finding is consistent with
having wild type APC protein. Interestingly, chromosome
structure was not stable in RKO as evidenced by high number
of rearranged chromosomes which was not expected for MSI
cell line. Previously, we have describedMSI cell line with spe-
cific tendency to acquire structural rearrangements most of
which were balanced translocations [30] but the structural
rearrangements observed in RKO were mostly unbalanced
as seen by M-FISH and reflected by the high copy number
changes observed by CGH. The combination of MSI and
structural chromosomal instability pattern, observed inRKO,
was reported previously in a poorly metastatic cell line
KM12C established in nude mice. Interestingly, some clones
of this line acquired high metastatic abilities in vivo and
showed polyploid karyotypes combined with MSI [31]. The
possibility of development of highlymetastatic cells from this
rare pattern of combined MSI and structural chromosomal
instability might have prognostic application and deserves
further analysis in clinical studies.
Consistent with the structural instability in RKO, we
observed high frequencies of LOH in primary tumors with
membranous 𝛽-catenin at the majority of the tested loci
comparable to the LOH frequency in tumors with nuclear
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𝛽-catenin. The LOH analysis also showed that some specific
events are selected for in tumors withmembranous𝛽-catenin
(2p25.1, 6p25.1) consistent with the down regulation of
nearby genes (EPCAM, SERPINB1) observed by expression
microarray analysis. The loss of EPCAM was reported in
Lynch syndrome cancers and germline deletion of this gene
was associated with predisposition to colorectal cancer in
Lynch syndrome [32–34]. This is relevant to the observation
that tumors with inactive Wnt/membranous 𝛽-catenin were
overrepresented among familial colon cancer [6]. Regarding
the mechanism of structural chromosomal instability in
RKO, we searched the list of differentially expressed genes
for DNA repair genes’ alteration but we could not find good
targets with the exception of ERCC1 and RECQL which were
rather upregulated in RKO. Overall, the tendency for struc-
tural chromosomal instability in RKO justifies more detailed
studies to analyze its extent, mechanism, and consequences
in the development of this subset of colorectal cancers.
The first observation from the expression microarray was
that cluster analysis based upon global gene expression profil-
ing corroborated our hypothesis that RKO cell line is unique
as it formed a distinct cluster separate from all other cell
lines. The high number of the differentially expressed genes
(611) exceeding the twofold change threshold and the large
number among these with a very high (>10) fold change (54
upregulated and 80 downregulated, total 134/611 genes) also
supports that the differences in the carcinogenic mechanisms
between these clusters are substantial. Considering known
and common pathways in colorectal carcinogenesis, a major
difference between RKO and other cell lines is the 𝛽-catenin
activation status. We cannot exclude the effect of other possi-
ble molecular differences (e.g., BRAFmutation status) on the
expression pattern of the cell lines. BRAF mutation is known
to correlate with MSI and CIMP, but RKO and most of other
cell lines were MSI-positive and CIMP-positive, regardless
of BRAF mutation status; hence this effect remains to be a
confounding factor. We characterized our primary tumors
for BRAF mutation; the frequencies we obtained were in
agreement with published reports on the occurrence ofBRAF
V600E mutation in sporadic and Lynch associated colorectal
cancers [35–37].
We then proceeded to verify whether or not selected
target genes have a role in well characterized categories of
primary colorectal cancers. We started by LOH analysis as it
was recently reported that LOH is an alternative mechanism
that plays a significant role in the pathogenesis of colorectal
cancers with chromosomal andmicrosatellite instability [38].
Overall, the majority of the tested loci were susceptible to
LOH in tumors with nuclear as well as membranous 𝛽-
catenin. Some loci showed high frequency of LOH consistent
with common areas of gains and losses reported in colorectal
cancers such as 7p15.2, 7q22.1, 8p22, 9p21.1, 12p12.3, 12q14.1,
17p13.1, 20q1.21, and 20q13.32 [8, 39]. Some target genes
associatedwith these loci were previously reported as putative
tumor suppressor in colorectal cancer includingMUC12 [40],
MTUS1 [38], and ARFGAP1/SMAP1 [41], while others were
novel targets with putative role in colorectal carcinogenesis
that deserves further analysis (NFE2L3, DGKI, ADAMTSL1,
RASSF8, DCTN2, GLIPR1, and ASGR1). Loci that were not
commonly reported as targets of gains, losses, or allelic imbal-
ances in colorectal cancers included 1q23.2, 2q11.2, 5q35.2,
11q22.3, and 11q24.1 and their associated target genes also
included known tumor suppressors/immune killers such as
IL18 [42],OPCML/OBCAM [43], or novel colon cancer genes
(IFI16, RGS4, DEDD, AFF3, SORL1, and PDLIM7).
The immunohistochemistry of selected target genes
(IFI16,RGS4,MCTP1,DGKI,OBCAM/OPCML, andGLIPR1)
in primary tumors confirmed that they were differentially
expressed in clinical specimens. DGKI and GLIPR1 showed
significant relationship with the 𝛽-catenin subcellular local-
ization in a pattern similar to that observed by the cDNA
expression microarray analysis of the cell lines. GLIPR1
(glioma pathogenesis-related protein 1) is a p53 target gene
that has p53-dependent and p53-independent proapoptotic
activities in tumor cells [44]. It is downregulated in glioma
and prostate cancer and it could be a potential therapeutic
target for prostate cancer [45, 46]. Our data show that it is
also a potential tumor suppressor in colorectal cancer and
its expression is downregulated in association with 𝛽-catenin
activity. DGKI (diacylglycerol kinase, iota) is a member
of type IV diacylglycerol kinase subfamily which regulates
the intracellular concentration of diacylglycerol through its
phosphorylation. The specific role of this particular enzyme
is undetermined and very few publications are available on
this gene in general. Interestingly, DGKI was listed among
genes mutated in melanoma as identified by next generation
sequencing and also among hypermethylated gene list iden-
tified by whole-genome methylation analysis of glioblastoma
[47, 48]. Our data suggest that DGKI is a novel potential
tumor suppressor in colorectal cancers and its expression is
downregulated subsequent to 𝛽-catenin activation too.
Then we proceeded with methylation analysis as several
lines of evidence suggested close interactions between the
epigenetic system and Wnt signaling [49–51]. We selected
CMTM3, DGKI, DLC1, and OPCML from the list of genes
overexpressed in RKO, and EPCAM and KLK10 from the list
of genes underexpressed in RKO. As discussed above, LOH
and immunohistochemistry supported the role of DGKI,
EPCAM, and OPCML in clinical colon cancer specimens.
Virtually all the genes were hypermethylated to some degree
in clinical specimens of colon cancer, with CMTM3, DGKI,
andOPCML showing the highest frequencies (range 78%–98)
and the most significant methylation degree compared to the
matching normal tissues (Figure 4). CMTM3 gene belongs to
the chemokine-like factor gene superfamily, a novel family
that is similar to the chemokine and the transmembrane
4 superfamilies of signaling molecules and it is located at
the potential tumor suppressor locus 16q22.1. CMTM3 was
shown to be silenced by promotormethylation in a pilot study
of various types of carcinomas including few colon cancer
specimens and it was also shown to exert tumor suppressor
properties in vitro [52]. This report was corroborated by spe-
cific reports on its tumor suppressor properties in clear cell
lung cancer [53], gastric cancer [54], and testicular cancer
[55]. OPCML/OBCAM encodes a highly conserved protein
localized in the plasma membrane. It is a well-established
tumor suppressor of ovarian cancers that is frequently
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Figure 4: Frequency of promoter hypermethylation for all selected
genes in the three categories of tumors. 𝑦-axis indicates the percent-
age of tumors showing hypermethylation, based on cut-off values
given in Supplementary Table S4.
silenced by promoter hypermethylation and the detection of
methylation of OPCML promoter in ovarian cancer tissues
could have prognostic application [56]. It was found to be
frequently methylated in other cancers including those of the
lung and liver, and it was in the top-ranking hypermethylated
genes detected by high density DNA methylation microar-
ray screening of small number of colorectal cancers [57].
The DGKI gene was discussed above. Overall, the current
evidence of CMTM3, DGKI, and OPCML gene promoter
hypermethylation suggests that silencing of these genes is a
significant event in colorectal carcinogenesis given the very
high frequency of methylated tumors of various categories
as well as the significant methylation dosage ratios in tumors
compared to normal mucosa.
KLK10 provided the best example of subgroup-specificity,
being hypermethylated in 48% of Lynch syndrome-colorectal
cancers compared to 8% for sporadic MSI and 12% for spo-
radicMSS colorectal cancers. Growing evidence suggests that
many kallikreins are implicated in carcinogenesis and some
have potential as novel cancer and other disease biomarkers.
KLK10 is one of the fifteen kallikrein subfamily members
which encodes a secreted protein and may play a role in
suppression of tumorigenesis in breast and prostate cancers.
Interestingly,KLK10 has been recently shown to be associated
with prognosis of colon and other cancers [58–60]. EPCAM
was exclusively methylated in Lynch syndrome colorectal
cancers with a frequency of 30% which is interesting given
that germline deletion of EPCAM was reported to predispose
to colorectal cancer in Lynch syndrome through methylation
of MSH2 [32–34]. Our data shows that EPCAM itself could
be also susceptible to methylation in a small subset of Lynch
syndrome-related colorectal cancers.
Interestingly, 𝛽-catenin subcellular localization stratified
the tumors into two groups relative to hypermethylation,
with membranous (inactive) 𝛽-catenin being associated with
a higher frequency of hypermethylated genes compared to
nuclear (active) 𝛽-catenin. This is an intriguing observation
and supports previous evidence implicating epigenetic mod-
ifications as one important layer in the multilayered control
system responsible for cell-type specific regulation of Wnt
target genes [49].
This work analyzed the carcinogenic mechanisms of
colorectal cancers that lacks active 𝛽-catenin/TCF regulated
transcription using a model cell line and groups of primary
sporadic and hereditary colon cancers. The data illustrate
that these cancers might evolve through distinct cytogenetic
structural chromosomal instability and also involves distinct
groups of cancer-related genes which are susceptible to LOH
and methylation. The essential regulatory systems important
in colon cancer development (epigenetics,Wnt signaling, and
genetic instability) appeared to be closely connected. The
differentially expressed genes validated here could be used to
develop personalized tumor profiling.
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